June 8, 2015Open Access
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes
Key Points
Key points are not available for this paper at this time.
Abstract
Among patients with type 2 diabetes and established cardiovascular disease, adding sitagliptin to usual care did not appear to increase the risk of major adverse cardiovascular events, hospitalization for heart failure, or other adverse events. (Funded by Merck Sharp TECOS ClinicalTrials.gov number, NCT00790205.).
Connected Papers
Building similarity graph...
Analyzing shared references across papers
Discussion
Loading...
Authors
J
Jennifer B. Green
University of North Carolina at Chapel Hill
M
M. Angelyn Bethel
Paul W. Armstrong
General Cardiology
Journals
ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam)
New England Journal of Medicine
Actions
Institutions
University of Oxford
University of Toronto
University of North Carolina at Chapel Hill
References and Citations
Connected Papers
Building similarity graph...
Analyzing shared references across papers
Discussion
Loading...